Compare Stocks → Just Released: Insider's Secret to Trading Options (From Schaeffer’s Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKCANASDAQ:APLSNASDAQ:DCPHNASDAQ:QURENASDAQ:TCDA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AAPLSApellis Pharmaceuticals$49.93+2.5%$58.96$19.83▼$94.75$6.02B0.881.48 million shs1.25 million shsDCPHDeciphera Pharmaceuticals$14.62-0.3%$15.65$9.90▼$17.73$1.18B0.39523,050 shs401,815 shsQUREuniQure$4.56-4.0%$5.31$4.48▼$22.48$218.14M0.95975,900 shs635,794 shsTCDATricida$0.13$0.09▼$13.85$6.01M0.2217.62 million shs31.13 million shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%APLSApellis Pharmaceuticals+2.48%+3.96%-10.08%-24.63%-42.89%DCPHDeciphera Pharmaceuticals-0.34%-0.68%-4.44%+1.88%+0.69%QUREuniQure-4.00%-2.36%-14.77%-20.83%-76.59%TCDATricida0.00%0.00%0.00%0.00%0.00%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAPLSApellis Pharmaceuticals4.4498 of 5 stars4.42.00.04.41.92.50.6DCPHDeciphera Pharmaceuticals3.4043 of 5 stars3.40.00.03.82.71.70.6QUREuniQure1.9747 of 5 stars3.44.00.00.00.02.50.6TCDATricidaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKCAAkcea TherapeuticsN/AN/AN/AN/AAPLSApellis Pharmaceuticals2.87Moderate Buy$77.9356.09% UpsideDCPHDeciphera Pharmaceuticals2.80Moderate Buy$23.0057.32% UpsideQUREuniQure2.71Moderate Buy$32.00601.75% UpsideTCDATricidaN/AN/AN/AN/ACurrent Analyst RatingsLatest DCPH, TCDA, AKCA, APLS, and QURE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2024APLSApellis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$67.00 ➝ $57.004/15/2024APLSApellis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.004/9/2024APLSApellis PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.003/27/2024APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$60.003/20/2024DCPHDeciphera PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$14.00 ➝ $16.003/6/2024APLSApellis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$78.00 ➝ $79.003/4/2024APLSApellis PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$87.00 ➝ $89.003/4/2024QUREuniQureMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $7.003/1/2024QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $25.002/29/2024QUREuniQureThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$63.00 ➝ $8.002/28/2024APLSApellis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14APLSApellis Pharmaceuticals$396.59M15.18N/AN/A$1.64 per share30.45DCPHDeciphera Pharmaceuticals$163.36M7.23N/AN/A$4.38 per share3.34QUREuniQure$15.84M13.77N/AN/A$4.34 per share1.05TCDATricidaN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/AAPLSApellis Pharmaceuticals-$528.63M-$4.48N/A46.23N/A-133.34%-178.60%-60.41%5/7/2024 (Confirmed)DCPHDeciphera Pharmaceuticals-$194.94M-$2.29N/AN/AN/A-119.33%-49.44%-38.41%5/1/2024 (Estimated)QUREuniQure-$308.48M-$6.48N/AN/AN/A-1,947.09%-99.31%-37.65%5/14/2024 (Estimated)TCDATricida-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/ALatest DCPH, TCDA, AKCA, APLS, and QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/AAPLSApellis Pharmaceuticals-$0.55N/A+$0.55N/AN/AN/A 2/28/2024Q4 2023QUREuniQure-$1.54-$1.53+$0.01-$1.53$3.20 million$6.69 million2/27/202412/31/2023APLSApellis Pharmaceuticals-$0.73-$0.73N/A-$0.73$143.34 million$146.38 million 2/6/2024Q4 2023DCPHDeciphera Pharmaceuticals-$0.58-$0.54+$0.04-$0.54$45.93 million$48.30 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ADCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKCAAkcea TherapeuticsN/A12.1711.78APLSApellis Pharmaceuticals0.483.102.50DCPHDeciphera PharmaceuticalsN/A3.803.59QUREuniQure0.498.858.68TCDATricidaN/A4.874.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKCAAkcea Therapeutics19.27%APLSApellis Pharmaceuticals96.29%DCPHDeciphera Pharmaceuticals70.96%QUREuniQure78.83%TCDATricidaN/AInsider OwnershipCompanyInsider OwnershipAKCAAkcea Therapeutics1.50%APLSApellis Pharmaceuticals7.50%DCPHDeciphera Pharmaceuticals4.43%QUREuniQure4.05%TCDATricida35.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableAPLSApellis Pharmaceuticals702120.58 million111.54 millionOptionableDCPHDeciphera Pharmaceuticals35580.80 million77.22 millionOptionableQUREuniQure48047.84 million45.90 millionOptionableTCDATricida5755.67 million35.85 millionNot OptionableDCPH, TCDA, AKCA, APLS, and QURE HeadlinesSourceHeadlineSierraConstellation Partners Receives Industry Recognition for Work with Tricidafinance.yahoo.com - February 6 at 10:02 AMTricida Inc (TCDAQ)es.investing.com - January 13 at 10:29 AMEmerging Therapies in the Treatment of Clostridium difficile-Associated Diseasemedscape.com - May 30 at 8:27 AMVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo Financenews.google.com - April 18 at 12:45 AMMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital Journalnews.google.com - April 17 at 7:44 PMReal-time PCR as a Diagnostic Tool for Bacterial Diseasesmedscape.com - April 12 at 11:47 PMChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital Journalnews.google.com - April 10 at 8:38 AMChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital Journalnews.google.com - April 6 at 7:54 AMTricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360news.google.com - March 24 at 11:19 PMAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo Financenews.google.com - March 14 at 3:50 PMAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo Financenews.google.com - March 14 at 10:49 AMTricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360news.google.com - March 6 at 10:59 PMTroubled Adamis To Merge With Private DMK, Focus On ... - Scripnews.google.com - March 1 at 12:17 PMRelease Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360news.google.com - February 27 at 8:43 PMRenibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360news.google.com - February 21 at 8:22 PMSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comnews.google.com - February 18 at 1:53 AMTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comnews.google.com - February 18 at 1:53 AMTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - February 14 at 7:22 PMRising Serum Bicarbonate Lowers CKD Progression Risk in ... - Renal and Urology Newsnews.google.com - February 8 at 7:43 AMFirm Retention Summary: Tricida Inc.wsj.com - February 3 at 3:38 PMTricida's Chapter 11 Liquidation – Global Legal Chronicle - Global Legal Chroniclenews.google.com - January 29 at 8:47 AMTricida Gets OK To Seek Stalking Horse For Ch. 11 Auction - Law360news.google.com - January 26 at 6:43 PMWeak Fundamental Momentum Drags Tricida Inc. (TCDA) Lower - Marketing Sentinelnews.google.com - January 24 at 2:09 PMTricida Inc. (TCDA): This Stock is set to Soar Above its Peers - Invest Chroniclenews.google.com - January 24 at 9:08 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkcea TherapeuticsNASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Apellis PharmaceuticalsNASDAQ:APLSApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Deciphera PharmaceuticalsNASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.uniQureNASDAQ:QUREuniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.TricidaNASDAQ:TCDATricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.